Abstract:During hepatic fibrogenesis, quiescent hepatic stellate cells (HSC) become active and trans-differentiate into myofibroblast-like cells. This process coincides with an increase in cell proliferation, loss of stored vitamin A droplets, and excessive production and deposition of extracellular matrix components. HSC activation is coupled with the sequential expression of cytokine receptors, including platelet-derived growth factor-beta receptor (PDGF-betaR). Although the underlying mechanisms remain incompletely understood, it is widely accepted that oxidative stress plays critical roles in activation of HSC during hepatic fibrogenesis. We have recently demonstrated that the antioxidant (-)-epigallocatechin gallate (EGCG), a major component in green tea extracts, significantly inhibited the proliferation of passaged HSC. The aim of the present study is to elucidate the underlying mechanisms. Since PDGF is a potent mitogen for HSC and mediates the early proliferative response, it was hypothesized that EGCG might inhibit HSC proliferation by interfering with the PDGF signal transduction. In this report, we demonstrated that EGCG, in two steps, significantly and effectively inhibited the proliferation of primary and passaged HSC. The polyphenolic compound initiated its inhibitory action by rapidly blocking the phosphorylation of tyrosines in PDGF-betaR elicited by PDGF in serum. This action was short lived, persisting for a few hours. In addition, this antioxidant inhibited the gene expression of PDGF-betaR by blocking the activation of transcription factors activator protein-1 and NF-kappaB, which were required for the gene transcription. The latter action remained effective for no less than 48 hours. These results provided a novel insight into the mechanisms by which EGCG inhibits HSC growth. The inhibitory effect of the natural antioxidant, its long history of beverage consumption without adverse health effects, and higher potent antioxidant capability make it a good candidate for therapeutic treatment and prevention of hepatic fibrosis.

Inhibition of Liver Cancer Cell Proliferation and Migration by a Combination of (-)-epigallocatechin-3- Gallate and Ascorbic Acid

Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu2+.

Growth Inhibition of Prostate Cancer Cells by Epigallocatechin Gallate in the Presence of Cu<sup>2+</sup>

Growth Inhibition Of Prostate Cancer Cells By Epigallocatechin Gallate In The Presenceof Cu2+

Epigallocatechin Gallate-Β-lactoglobulin Nanoparticles Improve the Antitumor Activity of EGCG for Inducing Cancer Cell Apoptosis

Inhibitory Effects of (−)-Epigallocatechin-3-gallate on Esophageal Cancer

A New Molecular Mechanism Underlying the EGCG-mediated Autophagic Modulation of AFP in HepG2 Cells

Ascorbic Acid Inhibits Liver Cancer Growth and Metastasis in Vitro and in Vivo, Independent of Stemness Gene Regulation

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Synergistic Effects of Tea Polyphenols and Ascorbic Acid on Human Lung Adenocarcinoma SPC-A-1 Cells

Anti-metastatic and Differential Effects on Protein Expression of Epigallocatechin-3-gallate in HCCLM6 Hepatocellular Carcinoma Cells

Epigallocatechin Gallate Induces Chemopreventive Effects on Rats with Diethylnitrosamine‑induced Liver Cancer Via Inhibition of Cell Division Cycle 25A.

Combining gamma-tocopherol and aspirin synergistically suppresses colitis-associated colon tumorigenesis and modulates the gut microbiota in mice, and inhibits the growth of human colon cancer cells

Enhancement of (-)-epigallocatechin-3-gallate and theaflavin-3-3'-digallate induced apoptosis by ascorbic acid in human lung adenocarcinoma SPC-A-1 cells and esophageal carcinoma Eca-109 cells via MAPK pathways.

Unveiling the therapeutic potential of epigallocatechin gallate in liver cancer: insights from network pharmacology and in vitro assays

Proanthocyanidin Regulates NETosis and Inhibits the Growth and Proliferation of Liver Cancer Cells – In Vivo, In Vitro and In Silico Investigation

[Inhibitory Effect and Mechanism of (-)-epigallocatechin-3-gallate on HT29 and HCT-8 Colorectal Cancer Cell Lines and Expression of HES1 and JAG1].

New Epigallocatechin Gallate (Egcg) Nanocomplexes Co-Assembled With 3-Mercapto-1-Hexanol And Beta-Lactoglobulin For Improvement Of Antitumor Activity

Molecular mechanism of epigallocatechin-3-gallate in human esophageal squamous cell carcinoma in vitro and in vivo.

The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor

Inhibition of HepG2 cell proliferation by ursolic acid and polysaccharides via the downregulation of cyclooxygenase-2.